Transplantation and cellular therapy
Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.
Emily C Merkel, Ted Gooley, Monica S Thakar, Scott N Furlan, Corinne Summers, Danielle C Kirkey, Brandon Hadland, Lauri M Burroughs, Paul A Carpenter, Aleksandra Petrovic, Ross Goshorn, Robert Irwin, Marie Bleakley, Todd Cooper, Katherine Tarlock
Published: 202510.1016/j.jtct.2025.12.003
Abstract
BACKGROUND: Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with high-risk features undergoing hematopoietic cell transplantation (HCT) experience high rates of relapse. Hypomethylating agent azacitidine (AZA) has been…
Preview only. Read the full abstract at the source